Posted by AngTayKor > 14 minutes ago | Report Abuse

If you think Maybank analyst honestly helping retail investors to huat, then please hold on or buy even more.
--------------


In the state of euphoria, history lessons will be easily forgotten. To be a good trader, you also need to understand crowd psychology and remember history lessons.

Im merely reflecting experiences as a trader la, sharing my trading knowledge.

If you think Maybank analyst honestly helping retail investors to huat, then please hold on or buy even more.

Posted by Michaelchan2024 > 4 hours ago | Report Abuse

Trump told CNN on Sunday that he believed Harris would be easier to defeat.

A Trump win in the 2024 presidential election could have various implications, including:

Delay for TauRx: It might have to wait five more years for potential advancements or approvals.
----------------------


@Michael， you like to 自編自導自演？ 🤣🤣🤣

I think Biden already a Mild Cognitive Impairment patient liow on the way to becoming an AD Mild patient.

Some good traders got their initial training at playing poker. Calculated risk. Know when to hold n when to fold the cards. Control your emotions n read the other players.

I have never put down a single dollar on the casino table in my life. I dont have an edge over the house, so i avoid their game totally. I choose the battlefield where i have an edge.

In stock trading, there is a very important factor called trend. If you follow the trend, your probability of winning becomes higher. Stock trading is a probability game. Always watch the downside, the upside will take care of itself. Trade defensively, safety first. Have your own trading rules n follow your trading rules religiously.

You need to have an edge over others, a strategy that can be repeated with higher chance of probability. In casino payout, the house will have an edge so its a matter of average out long term play house sure win.

Yes @Koosan, a trader's mental psychology, strategy n self-discipline rank above charting skills.

As a trader, its all abt the timing n big swings, not the amt of time in the market n time spent posting in chat forums. Having caught over 10 big n small swings since stock price was below 3.00, I think thats equivalent profit of stock price rm8 to 9 liow when trader exited n pumped in all money into taurx.

Posted by benqwe12345 > 1 day ago | Report Abuse
willing to buy Taurx shares
Can I know the price?
------------
Posted by Michaelchan2024 > 9 hours ago | Report Abuse
My investment in Genting was never based on hoping for a miracle FDA approval of TauRx. To me, TauRx is a bait used by traders to con people into buying Genting shares.
----------

You sure you still want to buy Taurx shares? Got people here say Taurx useless la, Taurx is used to con investors leh...

Actually Taurx news are small swings only. The biggest swing was actually Pfizer and Moderna covid vaccine trial result success (early Nov 2020). Trader bought when below 3.00 for a few days only suddenly vaccine trial success, trader increased position size along the way and exited at 4.30+, made rm2m in profit in abt 2 weeks. Re-entered again during pull back consolidation near 4.00 zone and made over rm1m profit within 4 weeks. Taurx news peanuts return for this stock so far. Covid vaccine news was much much more powerful.

You guys very solid can hold a stock for years and years! Covid already more than 4 years ago but stock price still quite hopeless.

@Riaz, unfortunately FDA is not our friend. The FDA officials (civil service) are usually more cozy with large pharma MNCs due to future job prospects at the private sector.

Accelerated Approval. Its usually a 8 to 10 yrs temporary commercialisation Approval to sell the drug but need to do n complete another confirmatory trial within this duration. AA primarily deals with biomarkers like Tau reduction, NfL reduction, slowdown in brain shrinkage to gain quick temporary approval. For taurx's case, although our drug can totally halt cognition decline n even reverse back up (its a cure), our placebo arm was later found to be an active dose (a low dose MTC formula for blue pee discolouration). Hence using traditional full approval standards, i doubt FDA will give us full approval (didn't meet primary endpoints measurements when compared against placebo arm)

September meeting. FDA wants us to combine both AA and Full Approval sessions into 1 meeting instead of 2 separate meetings. KNN how to do both of them within a 60 min meeting? I think better focus on AA liow as Full Approval seems like a long shot to me due to trial placebo issues.

Alzheimer's biotech Asceneuron raises $100M to see if it can compete with Lilly, Biogen on tau

A small Swiss biotech has raised a $100 million Series C to start testing its oral small molecule for Alzheimer’s disease in a Phase 2 later this year.

Asceneuron, a Merck KGaA spinout, is developing the O-GlcNAcase (OGA) inhibitor ASN51 and is hoping to go up against the two leading drugmakers in the Alzheimer’s field: Eli Lilly and Biogen.

The 12-year-old biotech started raising the Series C around the beginning of the year, CEO Barbara Angehrn Pavik said in an interview. She joined last fall after helping Vifor exit to CSL for $11.7 billion as chief business officer. Asceneuron was light on specifics of the Phase 2 trial design, including whether it’d be a global study.

Led by Novo Holdings, the Series C is expected to fully fund the trial and potentially see whether ASN51 can be developed for additional conditions, including Parkinson’s and amyotrophic lateral sclerosis, according to new board member Naveed Siddiqi, a senior partner on the venture investments team at Novo Holdings.

In addition to Novo Holdings, other investors in the Series C include new backers EQT Life Sciences’ LSP Dementia Fund, OrbiMed and SR One, along with existing financial supporters M Ventures, Sofinnova Partners, GSK Equities Investments and Johnson & Johnson Innovation’s JJDC.
Race with Lilly, Biogen

Biogen and Lilly are also developing their own experimental medicines aiming to inhibit the OGA enzyme with the goal of slowing down or curbing the buildup of tau protein.

Biogen and Lilly’s current marketed drugs — Leqembi and Kisunla, respectively — go after the pesky protein amyloid. But their new medicines, alongside Asceneuron, seek to destroy tau. The neurodegenerative-linked protein comes after amyloid and can damage neurons upon accumulation.

Lilly is in the lead on the OGA front, with a Phase 2 of its drug LY3372689 estimated to wrap up this summer, according to the federal trials database. Biogen’s candidate, named BIIB113, completed a Phase 1 last year. Multiple other drugmakers are developing anti-tau treatments with different approaches.

Leqembi was approved in 2023, but has had a slow commercial rollout, and Kisunla secured FDA approval last month after multiple delays over the past year. These anti-amyloid drugs have to be infused, which can be a strain on healthcare systems and can cause logistical hurdles for patients, and they’ve come with safety concerns about brain swelling and bleeding.

“The infrastructure and cost of this is enormous, so what the field really needs is an oral, a pill, you could take at home. And what we picked up was that there is a new class coming through of OGA inhibitors, which Lilly, Biogen and Asceneuron are developing,” Siddiqi said.

“Lilly will hopefully validate this class later on this year, and then we are second after that in a very large market,” Siddiqi said. He said it’s believed that tau is “more highly correlated with the loss of your cognition than amyloid is.”

The field has been trying to tackle tau for years. Lilly, Biogen, Roche, AbbVie and others have attempted anti-tau approaches with monoclonal antibodies, but none of them panned out in key clinical studies. “If you want an efficacious tau-targeting approach or therapy, it really is going to need to influence the aggregation of tau inside the cell,” Asceneuron SVP of R&D Ryan Schubert said.
----------------------


Asceneuron's development stage now is like 19 years ago when Taurx initiated phase 2 REMBER trial using first generation MTC drug formula.

Posted by Balian de Ibelin > 17 hours ago | Report Abuse
no worries
tomorrow back to 4.60
--------------


A day trading whale. One day's lunch at a time.

Which territory? UAE + UK + USA + EU + CHINA (royal flush) all in, confirm 6.50 no problem

If...

Posted by Johnchew123 > 4 days ago | Report Abuse
Game Over = Genting , this stock no local n foreign BUY , situpid investor buy let losses run
Local n foreign fund all in contruction stock since second half 1 July start ,smart investor Buy let profit run
200 MA sudah koyak follow GenM ,now slowly plunge
Curent share price slowly plunge reflect QR August decrease ,once confirm decrease profit , 4.30 gurantee touch , sleeping another 3 month until further notice
------------

@Johnchew dont be too bearish leh... every dog will have its day 😀

@neohts, its maybank IB again! 😀

Last round was rights/ warrant exercise at usd1.5b but its for the very hardcore brave shareholders like ATK to swop in n bet showhand buy very big. Taurx still has reasonably good cash level with no cash burning clinical trials anytime soon. I think next fund raising will be after securing as many CAs as possible to bring up value first, then do a pre-ipo fund raising.

After UK approval usd15b valuation confirm way to high la. If UK + EU + China CAs secured (global mkt ex-usa), maybe usd15b can. Maybank analyst siow kia, not too long ago put taurx at usd1b value. Need to see if UK giving us Full Approval or Conditional Approval.

Posted by Michaelchan2024 > 2 hours ago | Report Abuse
Actually, I am not a teacher. I just enjoy discussing and learning about trading.
-----------

The first lesson for stock trading is cutloss. Not easy to master this aspect as it is against human nature. When time to cutloss decisively, most amateurs will be hoping for a rebound, invariably leading to bigger losses.

Posted by Michaelchan2024 > 15 minutes ago | Report Abuse
Actually, as a long-term investor, I focus more on understanding long-term trends and making strategic decisions rather than quick trading moves 😀
----------------


Chart wise, no meaningful long term trend for this stock for now. 4 years after covid crash, still stuck range bound from abt 4.00 to 5.20 zones over the past 3 years.

Real traders dont like to talk too much rubbish. Their focus have always been to recognise the trends and make real money out from it. Immediately Buy, Immediately Huat.

https://www.straitstimes.com/world/united-states/donald-trump-shot-in-right-ear-at-rally-secret-service-says-suspected-shooter-is-dead
Win liow. Maciam chen shui bian who staged his own assasination back then in the Taiwanese presidential elections.

The way Trump pumped his fist to the crowd after the failed assassination like a reality show 😅😅😅

Daniel G. Aaron, MD, JD @MedlawDan


My aunt, on Leqembi for early Alzheimer's, just died.
She suffered an hours-long seizure in her bed. Her friend broke into the apartment and got medical help. Discovered to have many brain microhemorrhages and edema. Dead within 24 hours.
12:52 AM · Jul 11, 2024


https://x.com/MedlawDan/status/1811081139257483582


More to come. Many more will be permanently harmed by severe brain bleeding + accelerated brain shrinkage.

Posted by Michaelchan2024 > 4 hours ago | Report Abuse
ATK is selling ..to push down GenB's share price.
-----------

Please la @Michael, which stock market guru taught you to buy high sell low??? If Im trading this stock recently, I would have sold at 4.80+. Some months ago there were people here talking abt selling at 5.20, 5.50, 5.80 etc. I knew most of the time the crowd will get it wrong and my chart is telling me around 4.90 is the conviction sell zone.

Following GenS stock price behaviour. Those who bought over the past 2 months after good GenS result all kena trapped high liow. Treacherous stock market.

Posted by Michaelchan2024 > 2 hours ago | Report Abuse
Run
---------

Good call earlier today @Michael your reading of price action has improved 😄

Wah @michael studying charts n TA over the weekend? 😀

Posted by neohts > 1 day ago | Report Abuse
that Thestar.com news is for ELI Lilly.
--------------

Specially for you @neohts. Lecanemab and Donanemab as Therapies for Alzheimer’s Disease: An Illustrated Perspective on the Data

Alberto J. Espay,1 Kasper P. Kepp,2 and Karl Herrup3
https://www.eneuro.org/content/eneuro/11/7/ENEURO.0319-23.2024.full.pdf


This paper should have elaborated more on accelerated brain shrinkage aspect of Mab class of drugs. Brain neurons dying at faster rate, meaning these treatments are definitely going in the wrong direction. Its a known fact that AD brains shrink faster than normal brains as this rate of brain shrinkage is the purest form of physical biomarker whether the drug is working well or not. These drugs are just giving weak symptomatic effect for 12 months, something Aricept can do much better 25 years ago. Beyond 12 months, the downward slopes shown on graphs are both parallel sloping, indicating these are just symptomatic drugs and not disease modifying as claimed. There has to be some serious brain damage done to those patients here, the real effects can only be seen after a few years of using these drugs.

Posted by neohts > 1 hour ago | Report Abuse
that Thestar.com news is for ELI Lilly.
----------

I know. I replied with links abt the truth of Donanemab. Pay abt US$50k/yr actual treatment for a useless intravenous drug with numerous PET / MRI scans and consultations + iffy trial results (see how they calculate final trial result by excluding those serious side effects/death patients who dropped out trial) + brain bleeding + accelerated brain shrinkage. Generic Aricept drug can produce even better results at 2% of actual treatment cost. Thats a real solid advancement not for Science but purely for doctors' and drug developer's profit! 👏👏👏

July 1, 2024 02:40 JST
TOKYO -- Japanese pharmaceutical company Eisai is developing an Alzheimer's disease treatment that targets a protein linked to symptoms, aiming to release it in the U.S. by fiscal 2030, Nikkei has learned.

Small-scale clinical trials are underway to confirm the safety of the drug candidate, which targets tau proteins. Such drugs, though difficult to develop, are expected to be highly effective if successful.

https://asia.nikkei.com/Business/Pharmaceuticals/Japan-s-Eisai-aims-for-2030-U.S.-release-of-new-Alzheimer-s-drug?del_type=4&pub_date=20240702070000&seq_num=21&si=13105016
--------------


We discovered this fact during 1980s, now then amyloid drug developers realise targeting Tau can produce much more powerful results. We are lightyears ahead of any real clinically credible AD drug.

https://x.com/AlbertoEspay/status/1800638243056058709

https://x.com/AlbertoEspay/status/1806646390031802876

https://x.com/DanClintonRN/status/1801414681883500698?t=quIksYT-SopFLU0Lhc25Nw&s=08

Then why are prescription drug companies still so profitable? @Balian can choose to consume fake prescription drugs sold at back alley. I will choose the real drug covered by medical insurance.

Posted by AngTayKor > 2024-01-27 02:13 | Report Abuse

Posted by Kikilala3188 > | Report Abuse
Taurx when will it be announcing? Especially U.K. FDA approval
---------------

ATK: UK MHRA's final decision on CA is unlikely to be within 2024. We still have to file in more submissions which will take abt 5 to 6 months to complete it, followed by another 6 to 9 months for the regulator's final decision.

FDA delayed our Type C meeting request (supposed to be end Jan, before Taurx AGM on 6 Feb @6pm). We are not even sure if FDA will agree to consider HMTM using the Accelerated Approval pathway. If yes, I think FDA's final decision for AA will probably be at least 1.5yrs away.
------------------


@Michael, my post dated 27/01/2024 accurate or not? Today, 01/07/2024, Taurx finally announced that they have completed UK submissions.

Posted by Johnchew123 >1 month ago | Report Abuse
24 May QR , Genting expect report net profit 250 mil to 300 mil , QR May announed Genting will trade between 5.20 to 5.50
------------
Posted by Johnchew123 >1 month ago | Report Abuse
Coming next week QR 24 th May ,if net profit can achieved 300 mil ,better than QR Feb 150 mil , one more time gap up , after that Genting will trade 5.20 to 5.50 for whole month JUN
-----------
Posted by Johnchew123 > 3 minutes ago | Report Abuse
Genting Singapore plunge to 84.5 sen today ,year 2024 low now ,Genting Singpore now as a parria stock
QR May from 88 sen up 93,5 sen ,
Genting soon will plunge to 4.55 ,
Genting now consider a parrria stock ,didn’t follow big picture
When KLCI plunge ,Genting folllow plunge , KLCI up , Genting also plunge
This stock can consider parria stock ,rubbish n uselsss ,wasting time invest this counter
No local n foreign fund buy , daily play by Ikan bilis
------------


Wah @John was super bullish, suddenly major U-turn super bearish now

Posted by KooSan > 6 minutes ago | Report Abuse
And after MAA? What is next? Another trial?
------------

If approve means can commercialise the drug liow. Commonwealth countries including Malaysia and Singapore can follow MHRA's decision

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
Businesswire July 01, 2024

Posted by Michaelchan2024 > 1 hour ago | Report Abuse
ATK's peculiar behavior is that he always tends to tell people to sell, which is typical of short sellers..
--------------

Its all in your mind @Michael. When Im talking history events like past RPTs, LKT sold huge volumes above 5.20 or some occasional negative things, perma bulls will think that Im preaching for everyone to sell. The crowd forgets things very quickly including my bullish Q1 profit forecast of rm600m before the actual Q1 result. They often will choose to retain info according to the state of their fickle mind. To set the record straight, I have never shorted a single stock of GenB. I depend on my own charting skills to trade. I think it is naive to think that posting fear mongering / super bullish posts here in i3 will influence the stock price.

Posted by Michaelchan2024 > 23 minutes ago | Report Abuse
ATK is always ATK. A good storyteller.
--------------

@Michael. it is not a glamorous thing to publicly declare here that I am very cash poor now and no money to trade stocks.

Posted by Michaelchan2024 > 1 hour ago | Report Abuse
@ATK, you mentioned you don't hold any Genting shares. However, what puzzles me is why you are here on the Genting forum?
-----------

Still observing price action and reaction so my trading skill not rusty + how the crowd is thinking for this stock. To become a better boyfriend, you need to understand your girlfriend very well. To trade a stock well, you need to understand the behaviour of the stock well. I still manage to nail the important top (5.20 zone) and bottom (4.45 zone) for this stock during 2024. Call this a trader's life long learning process, Im forever a student of the stock market. I treat this business very seriously. I trade to win money.

No money now, all showhand into Taurx, which I believe can give me much higher returns than stock trading. But some day I will take back all my Taurx investment capital and start stock trading business again.

Dont scare those seatrium investors leh... but in the stock mkt, never say never!

Seatrium a little risky now @michael.

This stock must be suffering from @Michaelchan nonstop cheering fatigue la.

GenS broke strong support. Mkt see its Rm865m Q1 profit no up?

For the past 3 yrs, this stock mostly trading between 4.30 to 5.30, with mid-point at 4.80. Hence below 4.80 could also be considered "cheap" relative to past 3 yrs of stock price performance.

Stock price has been "cheap" for almost 5 yrs liow. Everyone knows its cheap. But why is it still cheap after so long?

Charlie Munger: "Every Time You Hear 'EBITDA’, Substitute It With ‘Bull**** Earnings' ”